These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 22580530)

  • 21. Effects of selenium and exendin-4 on glucagon-like peptide-1 receptor, IRS-1, and Raf-1 in the liver of diabetic rats.
    Barakat GM; Moustafa ME; Bikhazi AB
    Biochem Genet; 2012 Dec; 50(11-12):922-35. PubMed ID: 22983684
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A new orally available glucagon-like peptide-1 receptor agonist, biotinylated exendin-4, displays improved hypoglycemic effects in db/db mice.
    Jin CH; Chae SY; Son S; Kim TH; Um KA; Youn YS; Lee S; Lee KC
    J Control Release; 2009 Feb; 133(3):172-7. PubMed ID: 18977255
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Neuroprotective effect of the glucagon-like peptide-1 receptor agonist, synthetic exendin-4, in streptozotocin-induced diabetic rats.
    Liu WJ; Jin HY; Lee KA; Xie SH; Baek HS; Park TS
    Br J Pharmacol; 2011 Nov; 164(5):1410-20. PubMed ID: 21323903
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pharmacology of exenatide (synthetic exendin-4): a potential therapeutic for improved glycemic control of type 2 diabetes.
    Nielsen LL; Young AA; Parkes DG
    Regul Pept; 2004 Feb; 117(2):77-88. PubMed ID: 14700743
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The effects of exendin-4 treatment on graft failure: an animal study using a novel re-vascularized minimal human islet transplant model.
    Sahraoui A; Winzell MS; Gorman T; Smith DM; Skrtic S; Hoeyem M; Abadpour S; Johansson L; Korsgren O; Foss A; Scholz H
    PLoS One; 2015; 10(3):e0121204. PubMed ID: 25793295
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effect of exendin-4 treatment upon glucose uptake parameters in rat liver and muscle, in normal and type 2 diabetic state.
    Arnés L; Moreno P; Nuche-Berenguer B; Valverde I; Villanueva-Peñacarrillo ML
    Regul Pept; 2009 Feb; 153(1-3):88-92. PubMed ID: 18804493
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Glucose-lowering and insulin-sensitizing actions of exendin-4: studies in obese diabetic (ob/ob, db/db) mice, diabetic fatty Zucker rats, and diabetic rhesus monkeys (Macaca mulatta).
    Young AA; Gedulin BR; Bhavsar S; Bodkin N; Jodka C; Hansen B; Denaro M
    Diabetes; 1999 May; 48(5):1026-34. PubMed ID: 10331407
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Control of liver glucokinase activity: A potential new target for incretin hormones?
    Francini F; Massa ML; Polo MP; Villagarcía H; Castro MC; Gagliardino JJ
    Peptides; 2015 Dec; 74():57-63. PubMed ID: 26524624
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effects of exendin-4 on glucose tolerance, insulin secretion, and beta-cell proliferation depend on treatment dose, treatment duration and meal contents.
    Arakawa M; Ebato C; Mita T; Hirose T; Kawamori R; Fujitani Y; Watada H
    Biochem Biophys Res Commun; 2009 Dec; 390(3):809-14. PubMed ID: 19836346
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Glucagon-like peptide-1 receptor is present on human hepatocytes and has a direct role in decreasing hepatic steatosis in vitro by modulating elements of the insulin signaling pathway.
    Gupta NA; Mells J; Dunham RM; Grakoui A; Handy J; Saxena NK; Anania FA
    Hepatology; 2010 May; 51(5):1584-92. PubMed ID: 20225248
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The glucagon-like peptide-1 analogue exendin-4 reverses impaired intracellular Ca(2+) signalling in steatotic hepatocytes.
    Ali ES; Hua J; Wilson CH; Tallis GA; Zhou FH; Rychkov GY; Barritt GJ
    Biochim Biophys Acta; 2016 Sep; 1863(9):2135-46. PubMed ID: 27178543
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Glucagon-like peptide-1 receptor activation stimulates hepatic lipid oxidation and restores hepatic signalling alteration induced by a high-fat diet in nonalcoholic steatohepatitis.
    Svegliati-Baroni G; Saccomanno S; Rychlicki C; Agostinelli L; De Minicis S; Candelaresi C; Faraci G; Pacetti D; Vivarelli M; Nicolini D; Garelli P; Casini A; Manco M; Mingrone G; Risaliti A; Frega GN; Benedetti A; Gastaldelli A
    Liver Int; 2011 Oct; 31(9):1285-97. PubMed ID: 21745271
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The GLP-1 analogue exenatide improves hepatic and muscle insulin sensitivity in diabetic rats: tracer studies in the basal state and during hyperinsulinemic-euglycemic clamp.
    Wu H; Sui C; Xu H; Xia F; Zhai H; Zhang H; Weng P; Han B; Du S; Lu Y
    J Diabetes Res; 2014; 2014():524517. PubMed ID: 25580440
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Exendin-4 increases insulin sensitivity via a PI-3-kinase-dependent mechanism: contrasting effects of GLP-1.
    Idris I; Patiag D; Gray S; Donnelly R
    Biochem Pharmacol; 2002 Mar; 63(5):993-6. PubMed ID: 11911852
    [TBL] [Abstract][Full Text] [Related]  

  • 35. High potency antagonists of the pancreatic glucagon-like peptide-1 receptor.
    Montrose-Rafizadeh C; Yang H; Rodgers BD; Beday A; Pritchette LA; Eng J
    J Biol Chem; 1997 Aug; 272(34):21201-6. PubMed ID: 9261127
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effects of prolonged exendin-4 administration on entero-insular axis of normal and streptozotocin-induced diabetic rats.
    Malendowicz LK; Macchi C; Nussdorfer GG; Nowak KW; Zyterska A; Ziolkowska A
    Int J Mol Med; 2003 Jun; 11(6):763-6. PubMed ID: 12736719
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Exendin-4 partly ameliorates - hyperglycemia-mediated tissue damage in lungs of streptozotocin-induced diabetic mice.
    Oztay F; Sancar-Bas S; Gezginci-Oktayoglu S; Ercin M; Bolkent S
    Peptides; 2018 Jan; 99():99-107. PubMed ID: 29225158
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Normalizing action of exendin-4 and GLP-1 in the glucose metabolism of extrapancreatic tissues in insulin-resistant and type 2 diabetic states.
    Moreno P; Nuche-Berenguer B; Gutiérrez-Rojas I; Acitores A; Sancho V; Valverde I; González N; Villanueva-Peñacarrillo ML
    J Mol Endocrinol; 2012 Feb; 48(1):37-47. PubMed ID: 22065862
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Glucagon-like peptide-1 and islet lipolysis.
    Sörhede Winzell M; Ahrén B
    Horm Metab Res; 2004; 36(11-12):795-803. PubMed ID: 15655711
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Acute activation of central GLP-1 receptors enhances hepatic insulin action and insulin secretion in high-fat-fed, insulin resistant mice.
    Burmeister MA; Ferre T; Ayala JE; King EM; Holt RM; Ayala JE
    Am J Physiol Endocrinol Metab; 2012 Feb; 302(3):E334-43. PubMed ID: 22094469
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.